Recent advances in understanding and managing rhabdomyosarcoma
Open Access
- 12 May 2015
- journal article
- review article
- Published by H1 Connect in F1000Prime Reports
- Vol. 7 (59), 59
- https://doi.org/10.12703/p7-59
Abstract
Rhabdomyosarcoma is the most common childhood soft tissue sarcoma and the fourth most common pediatric solid tumor. For most patients, treatment consists of a multimodality approach, including chemotherapy, surgery, and/or radiotherapy. To guide treatment, patients with rhabdomyosarcoma are risk stratified based on a number of factors. These factors include clinical group, which depends largely on the extent of resection and nodal involvement, and stage, which takes into account tumor size, invasion, nodal involvement, and disease site. Histology of the tumor and age at diagnosis are also factored into risk stratification. Recent advances in understanding the biology of the disease have allowed for the further sub-classification of rhabdomyosarcoma. In addition, elucidation of additional clinical features associated with poor prognosis has allowed for better understanding of risk and provides more clarity regarding those patients who require more intensive therapy. Many areas of active investigation are ongoing, including the following: further delineation of the biological underpinnings of the various disease subtypes with the possibility of molecularly targeted therapy; a better understanding of clinical risk factors, including the evaluation and management of potentially involved lymph nodes; determination of the appropriate role of post-treatment imaging and assessment of response to therapy; and incorporation of advanced radiotherapeutic techniques, including conformal intensity-modulated photon and proton therapy.This publication has 29 references indexed in Scilit:
- Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001–2009PEDIATRICS, 2014
- FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion GeneClinical Cancer Research, 2014
- Myogenin, AP2β, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in RhabdomyosarcomaThe American Journal of Surgical Pathology, 2014
- Targeting Oxidative Stress in Embryonal RhabdomyosarcomaCancer Cell, 2013
- Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar RhabdomyosarcomaMolecular Cancer Therapeutics, 2013
- Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar RhabdomyosarcomaAmerican Journal of Clinical Pathology, 2013
- PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group reportPediatric Blood & Cancer, 2013
- FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar RhabdomyosarcomaClinical Cancer Research, 2012
- Fusion Gene-Negative Alveolar Rhabdomyosarcoma is Clinically and Molecularly Indistinguishable from Embryonal RhabdomyosarcomaJournal of Clinical Oncology, 2010
- Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial: A Report from the Children's Oncology GroupThe Journal of Molecular Diagnostics, 2006